Author: Ragothaman Srinivasan

Important Biotech Catalysts For September 15, 2022 – End Of The Day Summary – Kymera Therapeutics (NASDAQ:KYMR), Edwards Lifesciences (NYSE:EW), Alnylam Pharmaceuticals (NASDAQ:ALNY), Candel Therapeutics (NASDAQ:CADL), Incyte (NASDAQ:INCY), Jasper Therapeutics (NASDAQ:JSPR), Celsion (NASDAQ:CLSN), Lipocine (NASDAQ:LPCN), Regeneron Pharmaceuticals (NASDAQ:REGN), Tenax Therapeutics (NASDAQ:TENX), Omeros (NASDAQ:OMER), Pfizer (NYSE:PFE)

[ad_1] Pfizer PFE announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals…

Spectrum Pharmaceuticals (NASDAQ:SPPI), Immunocore Hldgs (NASDAQ:IMCR), Allakos (NASDAQ:ALLK), AstraZeneca (NASDAQ:AZN), Merck & Co (NYSE:MRK), IMAC Holdings (NASDAQ:BACK), Arcutis Biotherapeutics (NASDAQ:ARQT), Adaptimmune Therapeutics (NASDAQ:ADAP), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX) – Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary

[ad_1] The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ SPPI lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.…

Silence Therapeutics (NASDAQ:SLN), Alnylam Pharmaceuticals (NASDAQ:ALNY), Eli Lilly (NYSE:LLY), Amryt Pharma (NASDAQ:AMYT), SCYNEXIS (NASDAQ:SCYX), SINTX Technologies (NASDAQ:SINT), Ocuphire Pharma (NASDAQ:OCUP), Regeneron Pharmaceuticals (NASDAQ:REGN), VistaGen Therapeutics (NASDAQ:VTGN), Axsome Therapeutics (NASDAQ:AXSM), Lyra Therapeutics (NASDAQ:LYRA), Revance Therapeutics (NASDAQ:RVNC) – Important Biotech Catalysts For September 8, 2022 – End Of The Day Summary

[ad_1] The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ RVNC lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severecfrown lines…